Track Mounjaro^® & Zepbound^®
Tirzepatide Injection Tracker

Track your weekly tirzepatide injections, monitor your dose escalation from 2.5 mg through 15 mg, visualize estimated medication levels, and log your weight loss journey — for branded pens and compounded vials.

About tirzepatide

What Is Tirzepatide?

Tirzepatide is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly — the first medication to activate both incretin receptors. It's administered as a once-weekly subcutaneous injection:

Mounjaro^®

FDA-approved for type 2 diabetes (2022). Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg single-dose pens. Titration starts at 2.5 mg for 4 weeks, then 5 mg, with further increases as determined by your provider.

Zepbound^®

FDA-approved for chronic weight management (2023). Same molecule and dose tiers as Mounjaro. In clinical trials (SURMOUNT program), participants achieved significant weight reduction at maintenance doses.

Compounded tirzepatide

Prepared by compounding pharmacies in multi-dose vials. Not FDA-approved as a finished drug product. Requires syringe-based dosing with concentration-dependent unit calculation.

Science

Why Tirzepatide Tracking Differs from Semaglutide

Dual receptor activation

Tirzepatide activates both GIP and GLP-1 receptors, unlike semaglutide which targets GLP-1 only. This dual mechanism has different pharmacokinetic properties that affect level estimation.

Six dose tiers

Tirzepatide has 6 available doses (2.5–15 mg) compared to semaglutide's range. Titration from starting dose to maintenance may take longer and involves more steps.

Half-life of ~5 days

Tirzepatide's elimination half-life is approximately 5 days. Dosy uses this published pharmacokinetic data to estimate your medication levels between weekly injections.

Higher injection volumes at top doses

At 12.5 mg and 15 mg, compounded tirzepatide may require larger draw volumes depending on concentration — making dose calculation and vial tracking especially important.

Dosy features

How Dosy Tracks Tirzepatide

Tirzepatide-specific PK modeling — Medication level estimates calibrated to tirzepatide's ~5 day half-life and dual-receptor pharmacokinetics.

6-tier dose tracking — Track your progression through all 6 dose tiers (2.5 mg → 15 mg) with clear history of when you titrated.

Injection logging & site rotation — Log each weekly injection with site tracking and smart rotation to prevent tissue damage over your long-term treatment.

Weight & nutrition monitoring — Chart your weight trend alongside your tirzepatide dose. Track meals and macros as your appetite changes.

Compounded vial support — Dose calculator and inventory tracking for compounded tirzepatide vials — any concentration from any pharmacy.

Apple Health & Health Connect sync — Automatically import weight readings from your smart scale and share data bidirectionally with your phone's health platform.

Medical Disclaimer

Dosy Health is an educational and tracking tool only. It does not provide medical advice, diagnosis, or treatment recommendations. All dosing decisions must be made by your healthcare provider.

Do not rely on any app, including Dosy, as a substitute for professional medical guidance. Always confirm your dose and injection instructions with your prescribing provider and pharmacist.

Dosy Health is not affiliated with, endorsed by, or associated with Novo Nordisk (manufacturer of Ozempic^®, Wegovy^®, Saxenda^®, and Victoza^®), Eli Lilly (manufacturer of Mounjaro^®, Zepbound^®, Trulicity^®, and Foundayo^®), or any compounding pharmacy.

Start Tracking Today

Free to download. Tracks Mounjaro, Zepbound, and compounded tirzepatide.

Soon

Sources

Eli Lilly. Mounjaro^® (tirzepatide) Prescribing Information. Revised 2024.
Eli Lilly. Zepbound^® (tirzepatide) Prescribing Information. 2023.
Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. DOI: 10.1056/NEJMoa2206038 (SURMOUNT-1).
Coskun T, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist." Molecular Metabolism, 2018. — mechanism of action and pharmacokinetics.
U.S. Food & Drug Administration. "FDA Approves New Medication for Chronic Weight Management." FDA News Release regarding Zepbound, 2023.